5-Methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide

Modify Date: 2025-08-25 18:58:39

5-Methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide Structure
5-Methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide structure
Common Name 5-Methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide
CAS Number 848057-98-7 Molecular Weight 354.324
Density 1.3±0.1 g/cm3 Boiling Point 391.2±42.0 °C at 760 mmHg
Molecular Formula C17H17F3N2O3 Melting Point N/A
MSDS N/A Flash Point 190.4±27.9 °C

 Use of 5-Methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide


SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].

 Names

Name sphinx
Synonym More Synonyms

  Biological Activity

Description SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].
Related Catalog
Target

IC50: 0.58 μM (SRPK1)[1]

In Vitro SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1]. SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1]. Western Blot Analysis[1] Cell Line: ARPE-19 cell line Concentration: 10 μM Incubation Time: 2 hours Result: Blocked EGF-induced phosphorylation of SRSF1 and SRSF2.
In Vivo SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1]. SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1]. Animal Model: C57/B6 mice with laser-induced CNV[1] Dosage: 10 ng Administration: Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 Result: Significantly reduced neovascular growth compared with saline-injected controls. Animal Model: Norway Brown rats with laser-induced choroidal neovascularization[1] Dosage: 25 ng (10 ng/uL) Administration: Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 Result: Significantly reduced the CNV area compared with saline injected controls.
References

[1]. Gammons MV, et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):6052-62.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 391.2±42.0 °C at 760 mmHg
Molecular Formula C17H17F3N2O3
Molecular Weight 354.324
Flash Point 190.4±27.9 °C
Exact Mass 354.119141
LogP 4.01
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.555

 Synonyms

2-Furancarboxamide, 5-methyl-N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-
MFCD07315693
5-Methyl-N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-2-furamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.